1] Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK [2] Manchester Centre for Genomic Medicine, Central Manchester University Hospitals NHS Foundation Trust, MAHSC, Manchester, UK.
1] Manchester Centre for Genomic Medicine, Institute of Human Development, Faculty of Medical and Human Sciences, University of Manchester, Manchester Academic Health Science Centre (MAHSC), Manchester, UK [2] School of Psychological Sciences, University Of Manchester, Manchester, UK.
Eur J Hum Genet. 2014 Mar;22(3):396-401. doi: 10.1038/ejhg.2013.143. Epub 2013 Jul 17.
While debate has focused on whether testing of minors for late onset genetic disorders should be carried out if there is no medical benefit, less is known about the impact on young people (<25 years) who have had predictive testing often many years before the likely onset of symptoms. We looked at the experiences of young people who had had predictive testing for a range of conditions with variable ages at onset and options for screening and treatment. A consecutive series of 61 young people who had a predictive test aged 15-25 years at the Clinical Genetic Service, Manchester, for HD, HBOC (BrCa 1 or 2) or FCM (Hypertrophic Cardiomyopathy or Dilated Cardiomyopathy), were invited to participate. Thirty-six (36/61; 59%) agreed to participate (10 HD, 16 HBOC and 10 FCM) and telephone interviews were audiotaped, transcribed and analysed using Interpretative Phenomenological Analysis. None of the participants expressed regret at having the test at a young age. Participants saw the value of pretest counselling not in facilitating a decision, but rather as a source of information and support. Differences emerged among the three groups in parent/family involvement in the decision to be tested. Parents in FCM families were a strong influence in favour of testing, in HBOC the decision was autonomous but usually congruent with the views of parents, whereas in HD the decision was autonomous and sometimes went against the opinions of parents/grandparents. Participants from all three groups proposed more tailoring of predictive test counselling to the needs of young people.
虽然对于未成年人进行晚期发病遗传疾病检测是否应该进行,是否存在医学获益存在争议,但对于已经进行预测性检测的年轻人(<25 岁)的影响却知之甚少,这些年轻人在症状可能出现之前的很多年前就已经进行了预测性检测。我们研究了患有各种发病年龄不同、筛查和治疗选择不同的疾病的年轻人的经历。我们邀请了在曼彻斯特临床遗传服务中心接受 HD、HBOC(乳腺癌 1 或 2 基因)或 FCM(肥厚型心肌病或扩张型心肌病)预测性检测的年龄在 15-25 岁的连续 61 名年轻人参加。其中 36 名(36/61;59%)年轻人同意参加(10 名 HD,16 名 HBOC 和 10 名 FCM),并对电话采访进行了录音、转录和使用解释现象学分析进行了分析。没有一个参与者对年轻时进行测试表示后悔。参与者认为预测试咨询的价值不在于促进决策,而在于提供信息和支持。在三个组中,父母/家庭在决定接受测试方面的参与存在差异。FCM 家庭的父母对测试有强烈的影响,HBOC 中的决定是自主的,但通常与父母的观点一致,而在 HD 中,决定是自主的,有时与父母/祖父母的意见相悖。来自所有三个组的参与者都提出了对预测性测试咨询进行更多的个性化,以满足年轻人的需求。